The product is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
<0.001 EU per 1 μg of the protein by the LAL method
Coagulation factor VII human
May be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures.
Examples of Clinical Use:
Human Factor VII complexes with tissue factor resulting in its activation to VIIa. It is the activated Factor VIIa that then binds to Factor X activating it to Factor Xa, as well as coagulation Factor IX is activated to Factor IXa. Factor Xa continues the coagulation cascade to eventually convert prothrombin to thrombin, which leads to the formation of a clot by converting fibrinogen to fibrin.
Mechanism of action:
Factor VII is required in the extrinsic clotting cascade. When there is vascular damage tissue factor (TF) is released which then interacts with Factor VII resulting in the formation of the activated complex VIIa. Factor VIIa then continues to activate coagulation factors in the cascade until a clot is formed.
Coagulation factor VII human is one of the important coagulation proteins in the human body. Coagulation Factor VII Human is a plasma protein that participates in the important link of the blood coagulation process. The main function of coagulation factor VII is to participate in the coagulation cascade and play a role in initiating the clotting process. During injury or bleeding, coagulation factor VII is activated and forms a complex with tissue factors, which then activates factor X, which promotes the formation of thrombin, which in turn triggers fibrin formation, which eventually leads to blood clotting. Deficiency or lack of clotting factor VII can lead to bleeding symptoms, such as hemophilia and other disorders with abnormal clotting function. Clinically, factor VII deficiency may require supplementary treatment such as exogenous plasma products or recombinant factor VIIa to restore clotting function. Overall, coagulation factor VII plays an important role in maintaining normal blood clotting function, and its related drugs and treatments are of great significance in the treatment of some diseases with abnormal clotting.
Clinical Application of Human F7 Protein
Human F7 (Coagulation factor VII human) can be used in many clinical applications, mainly involved in the treatment and control of coagulation dysfunction. (1) Treatment of hereditary coagulation factor VII defects: For Hemophilia A or Acquired factor VII deficiency, exogenous supplementation of Human F7 can help restore coagulation function and prevent or reduce the occurrence of bleeding events. (2) Surgical management of abnormal coagulation: In some surgical procedures, such as heart surgery, organ transplantation, etc., insufficient coagulation function may occur. Exogenous supplementation of Human F7 can be used as an adjunct to help control bleeding during surgery, providing additional clotting support. (3) Reversal of anticoagulants: Some anticoagulants, such as Warfarin, may cause an increased risk of bleeding. In emergency situations, if the anticoagulant state needs to be reversed and clotting function restored, exogenous supplementation of Human F7 may help reverse the effects of anticoagulants. It is important to note that the use of coagulation factor VII must be carried out under the guidance of a physician and evaluated and made based on the specific circumstances of the patient. The dosage and course of treatment should be determined according to the patient's coagulation indicators and clinical needs. The use of coagulation factor VII may be associated with certain risks, and the doctor will weigh the treatment effect and potential risks to make a decision.
Action mechanism of Human F7 Protein
The mechanism of action of Coagulation factor VII humans involves the initiation stage of the coagulation cascade. Specifically, when blood vessels are damaged or Tissue is damaged, clotting Factor VII is activated to form complexes that interact with tissue factors, called prothrombin complexes (TF-FVIIa). The TF-FVIIa complex plays a key role in initiating the clotting process. The TF-FVIIa complex works with other clotting factors to activate Factor X into Factor Xa. Factor Xa is involved in subsequent clotting cascades that eventually lead to the formation of Thrombin. Thrombin further catalyzes the conversion of Fibrinogen into fibrin polymers, which clot the damaged blood together to form a clot. The mechanism of action of coagulation factor VII plays an important role in the initial stage of the coagulation cascade and plays a key role in initiating the blood clotting process by interacting with tissue factors. Through this mechanism, coagulation factor VII participates in the normal blood clotting process. It is important to note that in addition to the normal clotting process, abnormalities or lack of clotting factor VII can lead to coagulation dysfunction and bleeding risks. In some cases, the synthetic clotting factor VIIa may be used as a treatment to restore clotting function or control bleeding.
Advantages and Disadvantages of Human F7 Protein
Advantages (1) For specific hereditary coagulation factor VII deficiency diseases, such as hemophilia, exogenous supplementation of coagulation factor VII can help restore coagulation function and reduce or prevent the occurrence of bleeding events. (2) In certain surgical procedures or special circumstances, exogenous supplementation of coagulation factor VII can be used as an adjoint to help control bleeding conditions and provide additional clotting support. (3) For some specific coagulation abnormalities, such as bleeding caused by anticoagulant drugs, exogenous supplementation of coagulation factor VII may help reverse the anticoagulant effect and help restore normal coagulation function. Disadvantages (1) There may sometimes be a risk of thrombosis when factor VII is used, especially at high doses and for long periods of time. Therefore, it is necessary to monitor thrombus formation in patients during use. (2) As an exogenous biologic, factor VII is expensive to produce and may be in short supply in some areas, increasing the economic and practical difficulty of use. (3) In non-hereditary disorders of coagulation, the application of coagulation factor VII is limited and needs to be carefully considered on a case-by-case basis.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.